ST. LOUIS, June 21 /PRNewswire-FirstCall/ -- GenoMed , a Next Generation Disease Management company whose business is global public health(TM), today announced that its CEO was invited to speak at the Department of Medicine of the University of Chicago about diseases associated with the angiotensin I-converting enzyme (ACE), including avian influenza (“bird flu”).
Dr. Skip Garcia, Chairman of the Medicine Department, invited GenoMed’s CEO, David Moskowitz, MD, for a two day Visiting Lectureship that ended yesterday. Dr. Garcia is a world-famous lung specialist whose research group is looking for drugs to decrease the “cytokine storm” created by the avian influenza virus.
GenoMed has filed patent applications claiming that ACE inhibitors and angiotensin II blockers can do exactly that. Furthermore, these drugs may be a near-universal viral antidote, because people who get sick from all viral diseases suffer from a “cytokine storm.” GenoMed’s viral antidote was included in the Project BioShield II Act of 2005, since it would be an ideal response to viral bioterrorism.
Said Dr. Moskowitz, GenoMed’s CEO and Chief Medical Officer, “GenoMed goes from the molecular mechanism of disease directly to practical treatments that are safe and useful at the population level. We’re extremely gratified that a world-class research institution like the University of Chicago is thinking along exactly the same lines.”
About GenoMed
GenoMed’s general viral antidote is being offered for any viral epidemic around the globe. In the U.S., GenoMed’s approach has worked well against West Nile virus encephalitis since 2003. Anyone on earth can download the protocol for avian influenza or West Nile virus for free from GenoMed’s website, http://www.genomed.com , at any time of day or night. GenoMed simply requests an email address to make clinical follow-up possible.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company’s) treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMed
CONTACT: David W. Moskowitz MD of GenoMed, +1-314-983-9933,dwmoskowitz@genomed.com
Web site: http://www.genomed.com/
